Long QT Syndrome

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Long QT Syndrome Screening in Newborns

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

Phase 1 Study of LQT-1213 in Healthy Adults

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Study of the Effect of GS-6615 in Subjects With LQT-3

KCNQ1 Cascade Screening

Prospective Identification of Long QT Syndrome in Fetal Life

Genetics of QT Prolongation With Antiarrhythmics

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients